National Quality Registry for Enhancement and Development of Evidence-Based Care in Heart Disease (SWEDEHEART)
Registry category: Cardiovascular diseases
Certification level: 1
Central personal data controller (CPUA): Region Uppsala
Swedeheart is a national quality registry for acute coronary care, coronary angiography, Percutaneous Coronary Intervention (PCI), cardiac computed tomography, cardiac surgery, secondary prevention and genetic cardiovascular diseases. The purpose of the Swedeheart registry is to support continuous improvement measures in acute coronary syndrome and cardiac interventions at all participating clinics. The long-term goal is to contribute to a reduction in mortality and morbidity in patients and increase the cost-effectiveness of care.
Acute myocardial infarction is the single most common cause of death in both men (16 percent) and women (11 percent). Acute cardiovascular disease is the leading cause of hospitalisation, representing about 16 percent of hospital care. Every year, about 60,000 patients receive care for acute coronary syndrome.
In 2014, 27,000 individuals developed MI, of whom 22,500 were hospitalised. The 30-day mortality after an MI was 26 percent for all patients and 11 percent for those hospitalised. Cardiovascular disease was the underlying cause of death in 36 percent of cases. Ischaemic heart disease accounted for 44 percent of cardiovascular causes.
Swedeheart contains data on:
- All patients with acute myocardial infarction, secondary prevention data for 1 year in those younger than 75 (RIKS-HIA and SEPHIA).
- All patients undergoing angiography, percutaneous coronary intervention (SCAAR), heart surgery (heart surgery registry) and percutaneous valve intervention (Percutaneous valve intervention registry).
- Patients with cardiogenetic disease (The cardiogenetic registry).
Note: Variable lists are updated on a regular basis and should therefore be seen as preliminary. For the latest version, please contact the registry.
Find contact information on the registry’s website.